What are the indications, dosing schedule, and contraindications for Skyrizi (risankizumab) in adult patients with moderate-to-severe plaque psoriasis?

Skyrizi (Risankizumab) for Moderate-to-Severe Plaque Psoriasis

Skyrizi is FDA-approved for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy, dosed at 150 mg subcutaneously at weeks 0,4, and then every 12 weeks thereafter. 1

Primary Indication

Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist specifically targeting the p19 subunit of IL-23. The FDA-approved indications include 1:

• Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
• Active psoriatic arthritis in adults
• Moderately to severely active Crohn's disease in adults
• Moderately to severely active ulcerative colitis in adults

Dosing Schedule for Plaque Psoriasis

The standard dosing regimen is 150 mg administered by subcutaneous injection at week 0, week 4, and every 12 weeks thereafter. 1

This dosing schedule is notably more convenient than many other biologics, with maintenance dosing only required every 3 months after the initial loading phase. The 2019 AAD-NPF guidelines, while published before full FDA approval, anticipated this dosing regimen with Level I evidence supporting 150 mg at weeks 0 and 4, then every 12 weeks 2.

Efficacy Data

Risankizumab demonstrates superior efficacy compared to both placebo and active comparators:

• Versus placebo: At week 16, approximately 75% of patients achieved PASI 90 (90% improvement in Psoriasis Area and Severity Index) compared to <5% with placebo 3
• Versus ustekinumab: Risankizumab showed superior PASI 90 response rates (75% vs 42-48%) at week 16 3
• Long-term efficacy: At 6 years (304 weeks) of continuous treatment, 86% of patients maintained PASI 90 response, with 54.2% achieving complete clearance (PASI 100) 4

The drug demonstrates consistent efficacy across patient subgroups regardless of baseline demographics, disease severity, body weight, or prior biologic exposure 5.

Special Site Involvement

Risankizumab shows effectiveness in high-impact anatomical sites:

• Scalp psoriasis: 72.5% complete clearance at 2 years 6
• Nail psoriasis: 64.7% complete clearance at 2 years 6
• Palmoplantar disease: 52.2% complete clearance at 2 years 6

Note that facial psoriasis may show more variable response and may require adjunctive topical therapy or additional interventions 7.

Contraindications

Absolute contraindication: History of serious hypersensitivity reaction to risankizumab-rzaa or any excipients 1

Relative contraindications and precautions:

• Active infection (including tuberculosis) or sepsis - defer treatment until infection resolves 1
• Untreated latent tuberculosis - must complete TB prophylaxis before initiating therapy 1

Pre-Treatment Requirements

Before initiating Skyrizi for any indication:

1. Complete age-appropriate vaccinations per current immunization guidelines 1
2. Evaluate for tuberculosis prior to treatment initiation 1
3. For inflammatory bowel disease indications only: Obtain baseline liver enzymes and bilirubin levels 1

Important Safety Considerations

• Avoid live vaccines during treatment; inactivated vaccines may be administered 1
• Infections: May increase infection risk - instruct patients to seek medical attention for signs of clinically important infection 1
• Hypersensitivity reactions: Serious reactions including anaphylaxis may occur 1

The long-term safety profile through 6 years shows low rates of treatment-emergent adverse events, with rates consistent across the treatment duration and no unexpected safety signals 4.

Psoriatic Arthritis Consideration

For patients with concomitant psoriatic arthritis, Skyrizi can be used alone or in combination with non-biologic disease-modifying antirheumatic drugs (DMARDs) 1. The same dosing schedule applies (150 mg at weeks 0,4, then every 12 weeks).

Clinical Positioning

Based on the 2019 AAD-NPF guidelines framework and subsequent evidence, risankizumab represents a highly effective first-line biologic option for moderate-to-severe plaque psoriasis. Its superior efficacy compared to ustekinumab and adalimumab 3, 8, combined with convenient every-12-week dosing and favorable long-term safety profile 4, make it an excellent choice for patients requiring systemic therapy. The drug demonstrates durable efficacy with maintained or improved responses over 6 years of continuous treatment 4.